Serum APE1 Autoantibodies: A Novel Potential Tumor Marker and Predictor of Chemotherapeutic Efficacy in Non-Small Cell Lung Cancer

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Dai, Nan ^a   Cao, Xiao Jing ^b   Li, Meng Xia ^a   Qing, Yi ^a   Liao, Ling ^a   Lu, Xian Feng ^a   Zhang, Shi Heng ^a   Li, Zheng ^a   Yang, Yu Xin ^a   Wang, Dong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Chongqing Hospital of Traditional Chinese Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APURINIC APYRIMIDINIC ENDONUCLEASE 1; APURINIC APYRIMIDINIC ENDONUCLEASE 1 ANTIBODY; APURINIC APYRIMIDINIC ENDONUCLEASE 1 ANTIGEN; AUTOANTIBODY; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; PLATINUM COMPLEX; UNCLASSIFIED DRUG; ANTIGEN; ANTINEOPLASTIC AGENT; APEX1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALUE; PROTEIN EXPRESSION; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84874597708     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058001     Document Type: Article

References (56)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Wang JB, Jiang Y, Wei WQ, Yang GH, Qiao YL, et al. (2010) Estimation of cancer incidence and mortality attributable to smoking in China. Cancer Causes Control 21: 959-965.
3. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
4. Postmus PE, (2008) Screening for lung cancer, an ongoing debate. Ann Oncol 19 (Suppl 7): vii25-27.
5. Konopa K, (2010) Do we have markers to select patients for adjuvant therapies of non-small-cell lung cancer? Ann Oncol 21 (Suppl 7): vii199-202.
6. Indovina P, Marcelli E, Maranta P, Tarro G, (2011) Lung cancer proteomics: recent advances in biomarker discovery. Int J Proteomics 2011: 726869.
7. Tufman A, Huber RM, (2010) Biological markers in lung cancer: A clinician's perspective. Cancer Biomark 6: 123-135.
8. Bharti A, Ma PC, Salgia R, (2007) Biomarker discovery in lung cancer-promises and challenges of clinical proteomics. Mass Spectrom Rev 26: 451-466.
9. Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, et al. (2010) Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 5: e15003.
10. Desmetz C, Mange A, Maudelonde T, Solassol J, (2011) Autoantibody signatures: progress and perspectives for early cancer detection. J Cell Mol Med 15: 2013-2024.
11. Folli F, Solimena M, Cofiell R, Austoni M, Tallini G, et al. (1993) Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 328: 546-551.
12. Tan HT, Low J, Lim SG, Chung MC, (2009) Serum autoantibodies as biomarkers for early cancer detection. FEBS J 276: 6880-6904.
13. Kobold S, Lutkens T, Cao Y, Bokemeyer C, Atanackovic D, (2010) Autoantibodies against tumor-related antigens: incidence and biologic significance. Hum Immunol 71: 643-651.
14. Atassi MZ, Casali P, (2008) Molecular mechanisms of autoimmunity. Autoimmunity 41: 123-132.
15. Nesterova M, Johnson N, Cheadle C, Cho-Chung YS, (2006) Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 1762: 398-403.
16. Iizasa T, Fujisawa T, Saitoh Y, Hiroshima K, Ohwada H, (1998) Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma. Cancer Immunol Immunother 46: 345-349.
17. Saleh J, Brunner C, Golzer R, Nastainczyk W, Montenarh M, (2006) p53 autoantibodies from patients with head and neck cancer recognise common epitopes on the polypeptide chain of p53. Cancer Lett 233: 48-56.
18. Macdonald IK, Allen J, Murray A, Parsy-Kowalska CB, Healey GF, et al. (2012) Development and validation of a high throughput system for discovery of antigens for autoantibody detection. PLoS One 7: e40759.
19. Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, et al. (2008) Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS One 3: e3409.
20. Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, et al. (2011) Clinical validation of an autoantibody test for lung cancer. Ann Oncol 22: 383-389.
21. Tureci O, Mack U, Luxemburger U, Heinen H, Krummenauer F, et al. (2006) Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 236: 64-71.
22. Karanikas V, Khalil S, Kerenidi T, Gourgoulianis KI, Germenis AE, (2009) Anti-survivin antibody responses in lung cancer. Cancer Lett 282: 159-166.
23. Evans AR, Limp-Foster M, Kelley MR, (2000) Going APE over ref-1. Mutat Res 461: 83-108.
24. Zhang YS, Fan S, Wang D, Yang Z, Xiang D, (2007) APE1 expression and its correlation with prognosis in non small cell lung cancer. Acta Academiae Medicinae Militaris Tertiae 29: 776-778.
25. Yoo DG, Song YJ, Cho EJ, Lee SK, Park JB, et al. (2008) Alteration of APE1/ref-1 expression in non-small cell lung cancer: the implications of impaired extracellular superoxide dismutase and catalase antioxidant systems. Lung Cancer 60: 277-284.
26. Wang D, Xiang DB, Yang XQ, Chen LS, Li MX, et al. (2009) APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer 66: 298-304.
27. Katsumata Y, Kawaguchi Y, Baba S (2011) Identification of Three New Autoantibodies Associated with Systemic Lupus Erythematosus Using Two Proteomic Approaches. Molecular & Cellular Proteomics 10.
28. Wang D, Luo M, Kelley MR, (2004) Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 3: 679-686.
29. Zhang Y, Wang J, Xiang D, Wang D, Xin X, (2009) Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor. Int J Oncol 35: 1069-1079.
30. Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, et al. (1995) p53 Antibodies in Patients with Various Types of Cancer: Assay, Identification, and Chatacterization. Clin Cancer Res 1: 1463-1469.
31. Schena M, Guarrera S, Buffoni L, Salvadori A, Voglino F, et al. (2012) DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients. DNA Repair (Amst).
32. Nuciforo PG, Luise C, Capra M, Pelosi G, d'Adda di Fagagna F, (2007) Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression. Carcinogenesis 28: 2082-2088.
33. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, et al. (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907-913.
34. Chapman CJ, Thorpe AJ, Murray A, Parsy-Kowalska CB, Allen J, et al. (2011) Immunobiomarkers in small cell lung cancer: potential early cancer signals. Clin Cancer Res 17: 1474-1480.
35. Neri M, Betta P, Marroni P, Filiberti R, Cafferata M, et al. (2003) Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases. Lung Cancer 39: 165-172.
36. Messmer BT, Nour-Omid TS, Ghia E, Sanchez AB, Kipps TJ, (2011) Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia. Leuk Res 35: 965-967.
37. Qiu J, Choi G, Li L, Wang H, Pitteri SJ, et al. (2008) Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 26: 5060-5066.
38. Gullo C, Au M, Feng G, Teoh G, (2006) The biology of Ku and its potential oncogenic role in cancer. Biochim Biophys Acta 1765: 223-234.
39. Fernandez Madrid F, (2005) Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett 230: 187-198.
40. Tell G, Damante G, Caldwell D, Kelley MR, (2005) The Intracellular Localization of APE1/Ref-1:More than a Passive Phenomenon? Antioxid Redox Signal 7: 365-384.
41. Tell G, Quadrifoglio F, Tiribelli C, Kelley MR, (2009) The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal 11: 601-620.
42. Hegde ML, Hazra TK, Mitra S, (2008) Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res 18: 27-47.
43. Sweasy JB, Lang T, DiMaio D, (2006) Is base excision repair a tumor suppressor mechanism? Cell Cycle 5: 250-259.
44. Bhakat KK, Mantha AK, Mitra S, (2009) Transcriptional regulatory functions of mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional protein. Antioxid Redox Signal 11: 621-638.
45. Singh KK, Kulawiec M, Still I, Desouki MM, Geradts J, et al. (2005) Inter-genomic cross talk between mitochondria and the nucleus plays an important role in tumorigenesis. Gene 354: 140-146.
46. Abbotts R, Madhusudan S, (2010) Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat Rev 36: 425-435.
47. Luo M, Kelley MR, (2004) Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res 24: 2127-2134.
48. Fishel ML, Kelley MR, (2007) The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med 28: 375-395.
49. Zinkernagel RM, (2000) What is missing in immunology to understand immunity? Nat Immunol 1: 181-185.
50. Fan J, Upadhye S, Worster A, (2006) Understanding receiver operating characteristic (ROC) curves. CJEM 8: 19-20.
51. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
52. Mitsudomi T, Suzuki S, Yatabe Y, Nishio M, Kuwabara M, et al. (1998) Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. J Natl Cancer Inst 90: 1563-1568.
53. Nagashio R, Sato Y, Jiang SX, Ryuge S, Kodera Y, et al. (2008) Detection of tumor-specific autoantibodies in sera of patients with lung cancer. Lung Cancer 62: 364-373.
54. Puglisi F, Aprile G, Minisini AM, Barbone F, Cataldi P, et al. (2001) Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas. Anticancer Res 21: 4041-4049.
55. Chattopadhyay R, Das S, Maiti AK, Boldogh I, Xie J, et al. (2008) Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1. Mol Cell Biol 28: 7066-7080.
56. Wu HH, Cheng YW, Chang JT, Wu TC, Liu WS, et al. (2010) Subcellular localization of apurinic endonuclease 1 promotes lung tumor aggressiveness via NF-kappaB activation. Oncogene 29: 4330-4340.